Skip to main content
Publications
Mellott CE, Jaworski R, Carrico J , Talbird SE , Dobrowolska I, Golicki D, Bencina G, Clinkscales M, Karamousouli E, Eiden AL, Sabale U. Public health impact and return on investment of the pediatric immunization program in Poland . Expert Rev Vaccines. 2023 Dec;22(11):1114-25. doi: 10.1080/14760584.2023.2275712
Ghaswalla P, Hitchens A , Candrilli SD , Carrico J , Hicks KA , Wilson E, Mehta D, Panozzo CA. Prevalence of underlying conditions associated with higher risk for severe RSV, influenza, or COVID-19 in adults in the United States, 2017-2018 . Poster presented at the IDWeek 2023; October 12, 2023. Boston, MA.
Barbieri M, Senese F, Mellott CE, Boccalini S, Carrico J , Bechini A, Talbird SE , Chen Y-H, Bencina G. Public health impact and return on investment of the pediatric national immunization program in Italy . Presented at the Italian Society of Hygiene, Preventive Medicine, and Public Health Conference; October 12, 2023. Cernobbio, Italy.
Carrico J , Mellott CE, Talbird SE , Bento-Abreu A, Merckx B, Vandenhaute J, Benchabane D, Dauby N, Ethgen O, Lepage P, Luyten J, Raes M, Simoens S, Van Ranst M, Eiden A, Nyaku MK, Bencina G. Public health impact and return on investment of Belgium's pediatric immunization program . Front Public Health. 2023 Jun 22;11:1032385. doi: 10.3389/fpubh.2023.1032385
Mellott C, Jaworski R, Carrico J , Clinkscales M, Talbird S , Dobrowolska I, Golicki D, Tsoumani E, Sabale U. Public health impact and return on investment of the pediatric immunization program in Poland . Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S117. doi: 10.1016/j.jval.2022.09.568
Carrico J , Mellott C, Talbird S , Abreu A, Merckx B, Vanderhaute J, Benchabane D, Dauby N, Ethgen O, Lepage P, Luyten J, Raes M, Simoens S, Van Ranst M, Bencina G, Nyaku MK. Economic evaluation of the pediatric immunization program in Belgium . Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.
Carrico J , Jia X, Zhao Y, Zhang J, Brodtkorb T , Mendelsohn A, Wu J, Feldman S, Armstrong A. Cost-effectiveness and budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs . Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a Suppl):S79. doi: 10.18553/jmcp.2019.25.10-a.s1